



This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	G protein–coupled receptor 116 (GPR116)	Cell culture and mouse studies suggest antagonizing GPR116 could be useful for treating metastatic breast cancer. In cell culture, small interfering RNA knockdown of GPR116 decreased invasion compared with no knockdown. In a mouse model of breast cancer metastasis, siRNA knockdown of GPR116 decreased bone and lung metastasis and increased survival compared with no knockdown. Next steps could include identifying selective inhibitors of GPR116 and testing them in mouse models of breast cancer.	Patent and licensing status undisclosed	Tang, X. et al. Cancer Res.; published online Sept. 5, 2013; doi:10.1158/0008-5472.CAN-13-1049 Contact: Jian Luo, East China Normal University, Shanghai, China e-mail: jluo@bio.ecnu.edu.cn
		SciBX 6(41); doi:10.1038/scibx.2013.1157 Published online Oct. 24, 2013		